Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Interest Income
Income earned on cash, deposits, and investments held by the company.
Tyra Biosciences, Inc.NASDAQ: TYRA
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $2.69M fell 27.3% year over year, ahead of the -31.7% change in trailing-twelve-month interest income. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +52.0% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -27.3% holds above the trailing-twelve-month pace of -31.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 12.82M USD
- Year-over-year change
- -27.6%
- 4-year CAGR
- +460.3%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.82M | -27.6% |
| FY2024 | 2024-12-31 | 17.7M | +63.7% |
| FY2023 | 2023-12-31 | 10.81M | +196.0% |
| FY2022 | 2022-12-31 | 3.65M | +27992.3% |
| FY2021 | 2021-12-31 | 13K | — |
Interest Income vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's LTM Mar 2026 interest income of $11.81M is the 6th highest of the 11 companies compared; the peer median is $14.29M.
- Its year-over-year change of -31.7% is the 8th highest of 11, against a peer median of -9.1%.
- Over three fiscal years its annual growth of +52.0% compares with a peer median of +49.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $66.09M | +84.4% | +121.9% | 305.8% | |
| LTM Mar 2026 | $24.72M | -2.7% | +84.6% | 34.5% | |
| LTM Jun 2026 | $21.03M | -8.1% | +42.2% | 12.4% | |
| LTM Mar 2026 | $19.73M | -35.4% | +49.8% | — | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $16.94M | +1.3% | +1547.0% | — |
| LTM Mar 2026 | $11.81M | -31.7% | +52.0% | — | |
| LTM Mar 2026 | $11.63M | -10.2% | — | — | |
| LTM Mar 2026 | $7.8M | -35.9% | +15.5% | 27.6% | |
| LTM Mar 2026 | $5.93M | -29.4% | +26.0% | 3.8% | |
| LTM Mar 2026 | $4.4M | +17.7% | +49.6% | 8.9% | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding TYRA) | $14.29M | -9.1% | +49.7% | 20.0% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.64M | 43.01M | 62.52M | 80.08M | 102.93M |
| Selling, General & Admin | 5.65M | 15.92M | 17.43M | 24.1M | 29.83M |
| Operating Expenses | 26.29M | 58.93M | 79.95M | 104.18M | 132.76M |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| EBITDA | (26.15M) | (55.03M) | (68.78M) | (85.96M) | (119.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (26.29M) | (58.93M) | (79.95M) | (104.18M) | (132.76M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 3.65M | 10.81M | 17.7M | 12.82M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6K) | 3.6M | 10.81M | 17.7M | 12.82M |
| Income Before Tax | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| EPS (Diluted) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| Weighted Avg Shares | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
| Weighted Avg Shares (Diluted) | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.